Nomura weighs rebuilding Hong Kong equity capital markets business
A rebound in Hong Kong share fundraising is prompting Nomura to review its equity capital markets presence in the city after scaling back the operation in recent years. The Japanese bank is discussing potential banker hires as it looks to benefit from stronger issuance activity and rising mainland Chinese capital flows into the financial hub.
Highlights
- Nomura is holding early internal discussions about hiring bankers to rebuild its Hong Kong equity capital markets business after partially retreating in 2023.
- Hong Kong equity fundraising rebounded in 2025 and remained strong in 2026, with companies raising HK$753.8 billion ($96 billion) in the first 10 months, up 47.5% year-on-year.
- Investor sentiment has cooled as scrutiny over AI-related equity valuations increases, but deal activity persists with seven companies debuting this week, including Sichuan Neautus Traditional Chinese Medicine rising 119.2% on debut.
Hiring discussions amid market recovery
As first reported by Reuters, Nomura is holding early internal discussions about hiring bankers for its Hong Kong equity capital markets business, according to two people with knowledge of the matter. The move would mark a possible reversal after the bank cut headcount and partially retreated from the business in 2023, when equity capital markets activity in Hong Kong and mainland China had weakened sharply.The discussions remain preliminary, and the bank has not finalised the size or timing of any hiring plan, the people said. In response to a Reuters query, a Nomura spokesperson said the firm constantly explores a range of business opportunities in light of client needs and market conditions, but does not comment on specific matters.
Equity capital markets bankers help companies raise funds through initial public offerings, secondary share sales and convertible bonds. A stronger Hong Kong platform could also help Nomura deepen ties with wealthy individuals and founders of privately held companies as more mainland Chinese capital flows into the city.
Fundraising revival supports strategic rethink
Hong Kong remains one of Asia's main venues for Chinese companies seeking to sell shares, and the market began recovering in early 2025 before rebounding sharply over that year. Although investor sentiment has cooled recently as valuations of AI-related offerings come under closer scrutiny, deal activity remains active.Seven companies, including four in the AI and chip sectors, made their market debuts this week in Hong Kong. Sichuan Neautus Traditional Chinese Medicine rose as much as 119.2% in its Hong Kong debut on Wednesday.
Companies raised HK$753.8 billion, or about $96 billion, through share sales including IPOs in the first 10 months of 2026, up 47.5% from a year earlier, according to Hong Kong Exchanges and Clearing Ltd. Even so, investors have become more cautious about whether AI-related offerings can deliver returns that justify heavy spending on computing power, land and energy.
As a reminder, we covered SSS equity gains and its defense of a long-term investment strategy amid paper-loss scrutiny.